546 related articles for article (PubMed ID: 37516849)
21. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
22. Biological effects of IL-21 on immune cells and its potential for cancer treatment.
Ma M; Xie Y; Liu J; Wu L; Liu Y; Qin X
Int Immunopharmacol; 2024 Jan; 126():111154. PubMed ID: 37977064
[TBL] [Abstract][Full Text] [Related]
23. Targeted cytokines for cancer immunotherapy.
Lode HN; Reisfeld RA
Immunol Res; 2000; 21(2-3):279-88. PubMed ID: 10852128
[TBL] [Abstract][Full Text] [Related]
24. CD25: A potential tumor therapeutic target.
Peng Y; Tao Y; Zhang Y; Wang J; Yang J; Wang Y
Int J Cancer; 2023 Apr; 152(7):1290-1303. PubMed ID: 36082452
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biology.
Voronov E; Apte RN
Curr Pharm Des; 2017; 23(32):4893-4905. PubMed ID: 28606052
[TBL] [Abstract][Full Text] [Related]
26. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
[TBL] [Abstract][Full Text] [Related]
27. Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer.
Viviani S; Salvini PM; Bidoli P; Camerini E; Spinazzé S; Arienti F; Rivoltini L; Motta V
Int J Biol Markers; 1993; 8(1):21-4. PubMed ID: 8388428
[TBL] [Abstract][Full Text] [Related]
28. The biology of interleukin-2.
Malek TR
Annu Rev Immunol; 2008; 26():453-79. PubMed ID: 18062768
[TBL] [Abstract][Full Text] [Related]
29. IL-33/ST2 as a potential target for tumor immunotherapy.
Jiang W; Lian J; Yue Y; Zhang Y
Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922
[TBL] [Abstract][Full Text] [Related]
30. Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion.
Trujillo-Cirilo L; Weiss-Steider B; Vargas-Angeles CA; Corona-Ortega MT; Rangel-Corona R
Cytokine; 2023 Oct; 170():156334. PubMed ID: 37598478
[TBL] [Abstract][Full Text] [Related]
31. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
32. Magnetic-Manipulated NK Cell Proliferation and Activation Enhance Immunotherapy of Orthotopic Liver Cancer.
Jiang H; Fu H; Min T; Hu P; Shi J
J Am Chem Soc; 2023 Jun; 145(24):13147-13160. PubMed ID: 37262421
[TBL] [Abstract][Full Text] [Related]
33. Molecular basis of Trypanosoma cruzi-induced immunosuppression. Altered expression by activated human lymphocytes of molecules which regulate antigen recognition and progression through the cell cycle.
Kierszenbaum F; Moretti E; Sztein MB
Biol Res; 1993; 26(1-2):197-207. PubMed ID: 7670532
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
36. Targeting interleukin-22 for cancer therapy.
Markota A; Endres S; Kobold S
Hum Vaccin Immunother; 2018; 14(8):2012-2015. PubMed ID: 29617184
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
[TBL] [Abstract][Full Text] [Related]
38. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
40. Signaling new therapeutic opportunities: cytokines in prostate cancer.
Chandran E; Meininger L; Karzai F; Madan RA
Expert Opin Biol Ther; 2022 Oct; 22(10):1233-1243. PubMed ID: 35930001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
